ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 19, 2011 | $1,410,000 | Replaced |
| 3rd Quarter - Report (this page) | Jan 21, 2012 | $520,000 | Replaced |
| 3rd Quarter - Amendment | Feb 20, 2012 | $1,420,000 | Yes |
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Labor Issues/Antitrust/Workplace LBR
Discussions regarding possible clarifications to labor rules, including wage and hour issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| KIRSTEN POWELL | — |
Taxation/Internal Revenue Code TAX
Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| DANNY LY | — |
Trade (domestic/foreign) TRD
Issues related to US position on intellectual property protections offered by US in international trade treaty
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| BRADLEY ALLEN ROSSIN | — |
Copyright/Patent/Trademark CPT
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| KIRSTEN POWELL | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Health Issues HCR
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| KIRSTEN POWELL | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Medicare/Medicaid MMM
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| KIRSTEN POWELL | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Consumer Issues/Safety/Products CSP
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Pharmacy PHA
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| ANDREW KAPLAN | — |
| DANNY LY | — |
| KIRSTEN POWELL | — |
| BRADLEY ALLEN ROSSIN | — |
| HEATHER STRAWN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.